Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 83.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,738 shares of the company's stock after selling 28,926 shares during the quarter. SG Americas Securities LLC's holdings in Janux Therapeutics were worth $261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. acquired a new stake in Janux Therapeutics in the second quarter worth about $5,715,000. Blue Owl Capital Holdings LP purchased a new position in shares of Janux Therapeutics in the second quarter worth about $1,676,000. The Manufacturers Life Insurance Company raised its position in Janux Therapeutics by 234.7% during the second quarter. The Manufacturers Life Insurance Company now owns 24,048 shares of the company's stock valued at $1,007,000 after acquiring an additional 16,864 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Janux Therapeutics in the second quarter valued at approximately $215,000. Finally, Samlyn Capital LLC grew its holdings in Janux Therapeutics by 9.6% in the second quarter. Samlyn Capital LLC now owns 324,703 shares of the company's stock valued at $13,602,000 after purchasing an additional 28,312 shares during the period. Institutional investors own 75.39% of the company's stock.

Insider Transactions at Janux Therapeutics

In other news, major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of the firm's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $47.00, for a total transaction of $7,427,457.00. Following the sale, the insider now owns 2,959,175 shares in the company, valued at $139,081,225. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 50,000 shares of the firm's stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $45.96, for a total value of $2,298,000.00. Following the transaction, the insider now directly owns 67,592 shares of the company's stock, valued at $3,106,528.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of the firm's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $47.00, for a total value of $7,427,457.00. Following the completion of the transaction, the insider now directly owns 2,959,175 shares in the company, valued at $139,081,225. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 395,610 shares of company stock worth $17,950,166 over the last quarter. 35.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on JANX shares. HC Wainwright reaffirmed a "buy" rating and issued a $63.00 price target on shares of Janux Therapeutics in a research note on Monday, August 19th. Wedbush reissued an "outperform" rating and set a $74.00 target price on shares of Janux Therapeutics in a research note on Thursday, August 8th. Cantor Fitzgerald reissued an "overweight" rating and set a $100.00 target price on shares of Janux Therapeutics in a research note on Monday, September 16th. Stifel Nicolaus started coverage on Janux Therapeutics in a research note on Friday, September 6th. They set a "buy" rating and a $70.00 target price for the company. Finally, Scotiabank lowered their target price on Janux Therapeutics from $47.00 to $42.00 and set a "sector perform" rating for the company in a research note on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $66.13.

Janux Therapeutics Stock Up 0.9 %

NASDAQ JANX traded up $0.46 during mid-day trading on Monday, hitting $50.49. The stock had a trading volume of 329,700 shares, compared to its average volume of 712,949. The company has a 50 day simple moving average of $46.09 and a 200 day simple moving average of $45.63. The company has a market cap of $2.62 billion, a price-to-earnings ratio of -41.39 and a beta of 3.54. Janux Therapeutics, Inc. has a 52-week low of $5.65 and a 52-week high of $65.60.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.20. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The firm had revenue of $8.90 million for the quarter, compared to analysts' expectations of $0.77 million. The business's revenue for the quarter was up 709.1% on a year-over-year basis. As a group, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.